SCYNEXIS reports 2021 net loss of $32.9M; BREXAFEMME revenues $1.1M in launch year

SCYNEXIS INC

BREXAFEMME net product revenue $1.1M full-year, $0.6M Q4; cost of product revenue $0.3M full-year.
Net loss $32.9M ($1.25/share) for FY2021 vs $55.2M ($5.15/share) in FY2020.
Cash $104.5M at year-end; projected runway into Q2 2023; plus $9.7M non-dilutive in early 2022.
Positive Phase 3 CANDLE for rVVC (65.4% vs 53.1% placebo, p=0.02); sNDA filing Q2 2022.
Initiating MARIO Phase 3 for invasive candidiasis; Orphan Medicinal Product Designation from EMA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.